Trial · NCT05162586
Participant flow48
How many started, completed or left each group, period by period.
1 to 20 of 48
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cohort A: Placebo | 26 | |
| Overall Study | STARTED | Cohort A: Enpatoran 25 mg | 24 | |
| Overall Study | STARTED | Cohort A: Enpatoran 50 mg | 26 | |
| Overall Study | STARTED | Cohort A: Enpatoran 100 mg | 26 | |
| Overall Study | STARTED | Cohort B (Part 1 + Part 2): Placebo | 95 | |
| Overall Study | STARTED | Cohort B (Part 2): Enpatoran 25 mg | 71 | |
| Overall Study | STARTED | Cohort B (Part 2): Enpatoran 50 mg | 74 | |
| Overall Study | STARTED | Cohort B (Part 1 + Part 2): Enpatoran 100 mg | 114 | |
| Overall Study | Participants With BILAG≥1A/2B Randomized in Error Due to Systemic Disease Activity | Cohort A: Placebo | 0 | |
| Overall Study | Participants With BILAG≥1A/2B Randomized in Error Due to Systemic Disease Activity | Cohort A: Enpatoran 25 mg | 1 | |
| Overall Study | Participants With BILAG≥1A/2B Randomized in Error Due to Systemic Disease Activity | Cohort A: Enpatoran 50 mg | 1 | |
| Overall Study | Participants With BILAG≥1A/2B Randomized in Error Due to Systemic Disease Activity | Cohort A: Enpatoran 100 mg | 0 | |
| Overall Study | Participants With BILAG≥1A/2B Randomized in Error Due to Systemic Disease Activity | Cohort B (Part 1 + Part 2): Placebo | 1 | |
| Overall Study | Participants With BILAG≥1A/2B Randomized in Error Due to Systemic Disease Activity | Cohort B (Part 2): Enpatoran 25 mg | 0 | |
| Overall Study | Participants With BILAG≥1A/2B Randomized in Error Due to Systemic Disease Activity | Cohort B (Part 2): Enpatoran 50 mg | 0 | |
| Overall Study | Participants With BILAG≥1A/2B Randomized in Error Due to Systemic Disease Activity | Cohort B (Part 1 + Part 2): Enpatoran 100 mg | 0 | |
| Overall Study | Cohort B Part 1 | Cohort A: Placebo | 0 | |
| Overall Study | Cohort B Part 1 | Cohort A: Enpatoran 25 mg | 0 | |
| Overall Study | Cohort B Part 1 | Cohort A: Enpatoran 50 mg | 0 | |
| Overall Study | Cohort B Part 1 | Cohort A: Enpatoran 100 mg | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05162586/flow